Senzime AB (publ) (SEZI.ST)
SEK 5.64
(-1.05%)
SEK 5.64
(-1.05%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 35.75 Million SEK | 154.77% |
| 2022 | 14.03 Million SEK | 27.81% |
| 2021 | 10.98 Million SEK | 17.6% |
| 2020 | 9.33 Million SEK | 39.13% |
| 2019 | 6.71 Million SEK | 108.81% |
| 2018 | 3.21 Million SEK | 1600.53% |
| 2017 | 189 Thousand SEK | -88.39% |
| 2016 | 1.62 Million SEK | 966.65% |
| 2015 | 152.62 Thousand SEK | -71.8% |
| 2014 | 541.15 Thousand SEK | -56.18% |
| 2013 | 1.23 Million SEK | 313.96% |
| 2012 | 298.34 Thousand SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 12.12 Million SEK | 11.71% |
| 2024 Q2 | 14.91 Million SEK | 23.08% |
| 2023 Q4 | 10.85 Million SEK | 18.53% |
| 2023 FY | 35.75 Million SEK | 154.77% |
| 2023 Q1 | 7.28 Million SEK | 60.18% |
| 2023 Q2 | 8.46 Million SEK | 16.11% |
| 2023 Q3 | 9.15 Million SEK | 8.18% |
| 2022 Q3 | 3.72 Million SEK | 9.32% |
| 2022 Q4 | 4.55 Million SEK | 22.31% |
| 2022 FY | 14.03 Million SEK | 27.81% |
| 2022 Q2 | 3.4 Million SEK | 44.13% |
| 2022 Q1 | 2.36 Million SEK | -36.48% |
| 2021 Q3 | 1.43 Million SEK | -67.29% |
| 2021 Q1 | 1.43 Million SEK | -58.87% |
| 2021 FY | 10.98 Million SEK | 17.6% |
| 2021 Q2 | 4.39 Million SEK | 205.5% |
| 2021 Q4 | 3.71 Million SEK | 158.84% |
| 2020 Q3 | 2.09 Million SEK | 81.0% |
| 2020 Q1 | 2.58 Million SEK | -3.68% |
| 2020 FY | 9.33 Million SEK | 39.13% |
| 2020 Q4 | 3.49 Million SEK | 66.7% |
| 2020 Q2 | 1.15 Million SEK | -55.27% |
| 2019 Q3 | 2.42 Million SEK | 98.69% |
| 2019 FY | 6.71 Million SEK | 108.81% |
| 2019 Q2 | 1.21 Million SEK | 216.36% |
| 2019 Q1 | 385 Thousand SEK | -85.59% |
| 2019 Q4 | 2.68 Million SEK | 11.07% |
| 2018 Q4 | 2.67 Million SEK | 1623.23% |
| 2018 FY | 3.21 Million SEK | 1600.53% |
| 2018 Q2 | 381 Thousand SEK | 5342.86% |
| 2018 Q1 | 7000.00 SEK | -53.33% |
| 2018 Q3 | 155 Thousand SEK | -59.32% |
| 2017 FY | 189 Thousand SEK | -88.39% |
| 2017 Q4 | 15 Thousand SEK | 0.0% |
| 2017 Q3 | - SEK | -100.0% |
| 2017 Q2 | 174 Thousand SEK | 0.0% |
| 2017 Q1 | - SEK | -100.0% |
| 2016 Q4 | 185 Thousand SEK | -79.44% |
| 2016 FY | 1.62 Million SEK | 966.65% |
| 2016 Q3 | 900 Thousand SEK | 72.74% |
| 2016 Q2 | 521 Thousand SEK | 2265.49% |
| 2016 Q1 | 22.02 Thousand SEK | -47.32% |
| 2015 Q3 | 33.33 Thousand SEK | 12.82% |
| 2015 Q4 | 41.81 Thousand SEK | 25.41% |
| 2015 Q1 | 47.92 Thousand SEK | 7.61% |
| 2015 FY | 152.62 Thousand SEK | -71.8% |
| 2015 Q2 | 29.55 Thousand SEK | -38.34% |
| 2014 Q1 | 356.26 Thousand SEK | -62.2% |
| 2014 FY | 541.15 Thousand SEK | -56.18% |
| 2014 Q2 | 128.6 Thousand SEK | -63.9% |
| 2014 Q3 | 11.75 Thousand SEK | -90.86% |
| 2014 Q4 | 44.54 Thousand SEK | 279.03% |
| 2013 FY | 1.23 Million SEK | 313.96% |
| 2013 Q3 | 2408.00 SEK | -98.34% |
| 2013 Q1 | 145.04 Thousand SEK | 533.0% |
| 2013 Q4 | 942.52 Thousand SEK | 39041.24% |
| 2013 Q2 | 145.04 Thousand SEK | 0.0% |
| 2012 FY | 298.34 Thousand SEK | 0.0% |
| 2012 Q4 | -33.49 Thousand SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -472.889% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 97.396% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 97.396% |
| Arcoma AB | 163.01 Million SEK | 78.067% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 82.473% |
| BICO Group AB (publ) | 2.23 Billion SEK | 98.403% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 93.742% |
| CellaVision AB (publ) | 677.29 Million SEK | 94.721% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -332.177% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -3562.265% |
| C-Rad AB (publ) | 424.61 Million SEK | 91.58% |
| Duearity AB (publ) | 1.65 Million SEK | -2061.669% |
| Dignitana AB (publ) | 86.06 Million SEK | 58.456% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -247.126% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.888% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -405.122% |
| Integrum AB (publ) | 104.11 Million SEK | 65.66% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -4083.227% |
| Mentice AB (publ) | 273.61 Million SEK | 86.932% |
| OssDsign AB (publ) | 112.15 Million SEK | 68.121% |
| Paxman AB (publ) | 210.11 Million SEK | 82.984% |
| Promimic AB (publ) | 37.07 Million SEK | 3.55% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -14553.279% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -53.814% |
| ScandiDos AB (publ) | 60.42 Million SEK | 40.833% |
| Sectra AB (publ) | 2.96 Billion SEK | 98.794% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 76.763% |
| SpectraCure AB (publ) | 318 Thousand SEK | -11143.396% |
| Stille AB | 294.89 Million SEK | 87.876% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 98.982% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 94.016% |